Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1290094.RAwHuasd4FTD_RbGQRzMfOO8bOki8fVJr1voEheVzOPp0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1290094.RAwHuasd4FTD_RbGQRzMfOO8bOki8fVJr1voEheVzOPp0130_assertion type Assertion NP1290094.RAwHuasd4FTD_RbGQRzMfOO8bOki8fVJr1voEheVzOPp0130_head.
- NP1290094.RAwHuasd4FTD_RbGQRzMfOO8bOki8fVJr1voEheVzOPp0130_assertion description "[The primary end-point was not met; low-dose erlotinib is not recommended for fit patients with NSCLC harbouring EGFR mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1290094.RAwHuasd4FTD_RbGQRzMfOO8bOki8fVJr1voEheVzOPp0130_provenance.
- NP1290094.RAwHuasd4FTD_RbGQRzMfOO8bOki8fVJr1voEheVzOPp0130_assertion evidence source_evidence_literature NP1290094.RAwHuasd4FTD_RbGQRzMfOO8bOki8fVJr1voEheVzOPp0130_provenance.
- NP1290094.RAwHuasd4FTD_RbGQRzMfOO8bOki8fVJr1voEheVzOPp0130_assertion SIO_000772 26174465 NP1290094.RAwHuasd4FTD_RbGQRzMfOO8bOki8fVJr1voEheVzOPp0130_provenance.
- NP1290094.RAwHuasd4FTD_RbGQRzMfOO8bOki8fVJr1voEheVzOPp0130_assertion wasDerivedFrom befree-2016 NP1290094.RAwHuasd4FTD_RbGQRzMfOO8bOki8fVJr1voEheVzOPp0130_provenance.
- NP1290094.RAwHuasd4FTD_RbGQRzMfOO8bOki8fVJr1voEheVzOPp0130_assertion wasGeneratedBy ECO_0000203 NP1290094.RAwHuasd4FTD_RbGQRzMfOO8bOki8fVJr1voEheVzOPp0130_provenance.